Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
eHealth Intervention for Medication Adherence in Breast Cancer Survivors (Edherence)

Tamoxifen and aromatase inhibitors are two oral hormonal therapies (OHT) that decrease the risk of breast cancer recurrence by over 30 %. Their efficacy however strongly depends on the duration

  • 0 views
  • 23 Apr, 2022
  • 1 location
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production. This

breast cancer staging
erbb2
letrozole
primary tumor
arimidex
  • 19 views
  • 13 May, 2022
  • 1 location
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (ENZENO)

differential mechanism of action from other endocrine therapy, such as tamoxifen, aromatase inhibitors, which indicates that direct blockage of ER might derive better clinical activity. However, due to

  • 0 views
  • 13 Apr, 2022
  • 8 locations
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

In ER+ and HER2- breast cancer(BC) patients for whom BCS is not feasible, we investigate the rate of BCS can be increased while decreasing unnecessary chemotherapy thru selective neoadjuvant chemotherapy or neoadjuvant endocrine therapy using tools of nodal status, Ki-67, and multigene assay(Mammaprint)

breast-conserving surgery
mammogram
erbb2
letrozole
HER2
  • 0 views
  • 25 Feb, 2022
  • 1 location
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)

DELFINO tial is designed to investigate the role of "OFS add on to TMX ", based on MMG density as a surrogate marker in premenopausal women Premise - MMG density as a surrogate marker of hormone therapy Assumption - "Add on OFS to TMX" would have further decrease of density …

endocrine therapy
hormone therapy
  • 3 views
  • 14 Feb, 2022
Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the …

anticoagulant
serous adenocarcinoma
progesterone
hysterectomy
endometrioid adenocarcinoma
  • 5 views
  • 12 Jun, 2021
  • 2 locations
Neoadjuvant With Trastuzumab Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive ER-positive Breast Cancer

This is a prospective Single-arm Study to Investigate the Efficacy and Safety of Neoadjuvant treatment with trastuzumab and pyrotinib plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer.

  • 0 views
  • 22 Oct, 2021
  • 1 location
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX

This is a multicenter, randomized, open-label, active comparator-controlled phase trial to compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX in patients with breast cancer.

immunohistochemistry
mammogram
estrogen
adjuvant chemotherapy
tamoxifen
  • 0 views
  • 12 Nov, 2021
  • 1 location
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .

HER2
erbb2
letrozole
tamoxifen
  • 0 views
  • 10 Mar, 2022
  • 1 location
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)

Eligible patients with estrogen receptor positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional …

mammogram
hormone therapy
letrozole
endocrine therapy
palbociclib
  • 3 views
  • 30 Apr, 2022
  • 4 locations